rethinkPeptides Search
Menu
Study breakdown

Ghrelin Binds to Human Brain and Pituitary With a Different Profile Than Synthetic GH Secretagogues

In VitroPreliminary evidence
The takeaway

Radiolabeled ghrelin bound to human hypothalamus and pituitary with high affinity but showed a different binding profile than synthetic GH secretagogues like hexarelin, suggesting receptor subtypes or binding modes differ.

Different binding profiles

Ghrelin and synthetic GH secretagogues bind human brain tissue differently — the receptor system is more complex than assumed

What the researchers found

125I-ghrelin bound to human hypothalamus and pituitary with high affinity but showed different binding characteristics than synthetic GHS (hexarelin, MK-0677), suggesting distinct receptor interaction modes or subtypes.

Why it matters

If ghrelin and synthetic GH secretagogues bind differently, they could have distinct therapeutic profiles. This explains why ghrelin (appetite + GH) and some synthetic GHS (GH-selective like ipamorelin) have different effect spectra.

How the study worked

In-vitro binding study using 125I-labeled ghrelin on human hypothalamic and pituitary membrane preparations. Competition binding with unlabeled ghrelin, hexarelin, and MK-0677 to characterize binding sites.

What this study cannot tell us

In-vitro binding on post-mortem tissue. Binding differences don't conclusively prove separate receptor subtypes. Human tissue availability limits sample size.

How to read the evidence

Preliminary in-vitro binding evidence in human tissue providing receptor pharmacology data suggesting system complexity.

When this study was published

Published in 2001. GHS receptor complexity has been further characterized, with constitutive activity and heterodimerization adding additional complexity.

The bigger picture

The GH secretagogue receptor system is more complex than a single receptor. Different binding modes for the natural ligand versus designed drugs could explain the diversity of effects seen with different compounds.

Questions still open

  • Do multiple GHS receptor subtypes exist in the human brain?
  • Does the binding difference explain ghrelin's appetite effect versus synthetic GHS's selectivity?
  • Can subtype-selective drugs be developed from this binding data?

Common questions

Don't all GH peptides work the same way?
No. This study shows ghrelin (the natural hormone) binds brain receptors differently from synthetic GH peptides. This explains why ghrelin strongly affects appetite while some synthetic peptides like ipamorelin primarily release GH.
What does this mean for choosing a GH peptide?
Different compounds have different receptor interactions, leading to different effects. Understanding these differences helps researchers develop compounds optimized for specific therapeutic goals.

Read the original research

Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland.

Journal of endocrinological investigation, 24(3), RC7-9

Citation

Muccioli, G; Papotti, M; Locatelli, V; Ghigo, E; Deghenghi, R. (2001). Binding of 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland.. Journal of endocrinological investigation, 24(3), RC7-9.